Vanda Pharmaceuticals Inc.

NasdaqGM:VNDA Stock Report

Market Cap: US$223.8m

Vanda Pharmaceuticals Management

Management criteria checks 3/4

Vanda Pharmaceuticals' CEO is Mihael Polymeropoulos, appointed in May 2003, has a tenure of 20.83 years. total yearly compensation is $4.27M, comprised of 19.1% salary and 80.9% bonuses, including company stock and options. directly owns 2.17% of the company’s shares, worth $4.86M. The average tenure of the management team and the board of directors is 6.3 years and 4.4 years respectively.

Key information

Mihael Polymeropoulos

Chief executive officer

US$4.3m

Total compensation

CEO salary percentage19.1%
CEO tenure20.8yrs
CEO ownership2.2%
Management average tenure6.3yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Feb 15
Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Feb 13

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Feb 10
Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Nov 11
News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

May 12
One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

Vanda Pharmaceuticals: What The Recent Partnership Entails

Oct 06

Vanda Pharma, OliPass collaborate to develop oligonucleotide-based therapeutics

Sep 29

Vanda Pharmaceuticals Q2 Earnings Preview

Aug 02

Vanda Pharmaceuticals: Strong Pipeline Developments To Power Long-Term Upside

May 17

Vanda: A Dual Growth And Value Player

Apr 11

Analysts Are More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

Feb 27
Analysts Are More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

Vanda: A Prudent Business With Upsides

Dec 30

An Intrinsic Calculation For Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Suggests It's 32% Undervalued

Nov 01
An Intrinsic Calculation For Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Suggests It's 32% Undervalued

Is There An Opportunity With Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) 47% Undervaluation?

Jun 28
Is There An Opportunity With Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) 47% Undervaluation?

It's Unlikely That The CEO Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Will See A Huge Pay Rise This Year

Jun 03
It's Unlikely That The CEO Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Will See A Huge Pay Rise This Year

This Insider Has Just Sold Shares In Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Mar 04
This Insider Has Just Sold Shares In Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

CEO Compensation Analysis

How has Mihael Polymeropoulos's remuneration changed compared to Vanda Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

US$3m

Sep 30 2023n/an/a

US$12m

Jun 30 2023n/an/a

US$15m

Mar 31 2023n/an/a

US$16m

Dec 31 2022US$4mUS$815k

US$6m

Sep 30 2022n/an/a

US$6m

Jun 30 2022n/an/a

US$11m

Mar 31 2022n/an/a

US$18m

Dec 31 2021US$6mUS$769k

US$33m

Sep 30 2021n/an/a

US$34m

Jun 30 2021n/an/a

US$32m

Mar 31 2021n/an/a

US$32m

Dec 31 2020US$3mUS$746k

US$23m

Sep 30 2020n/an/a

US$19m

Jun 30 2020n/an/a

US$114m

Mar 31 2020n/an/a

US$117m

Dec 31 2019US$4mUS$721k

US$116m

Sep 30 2019n/an/a

US$122m

Jun 30 2019n/an/a

US$28m

Mar 31 2019n/an/a

US$22m

Dec 31 2018US$4mUS$700k

US$25m

Sep 30 2018n/an/a

US$13m

Jun 30 2018n/an/a

US$1m

Mar 31 2018n/an/a

-US$5m

Dec 31 2017US$6mUS$675k

-US$16m

Compensation vs Market: Mihael's total compensation ($USD4.27M) is above average for companies of similar size in the US market ($USD1.46M).

Compensation vs Earnings: Mihael's compensation has been consistent with company performance over the past year.


CEO

Mihael Polymeropoulos (63 yo)

20.8yrs

Tenure

US$4,269,410

Compensation

Dr. Mihael H. Polymeropoulos, M.D., founded Vanda Pharmaceuticals, Inc. in 2003. He serves as Chairman of The Board at Vanda Pharmaceuticals Inc since June 2021 and has been its Chief Executive Officer, Pr...


Leadership Team

NamePositionTenureCompensationOwnership
Mihael Polymeropoulos
Founder20.8yrsUS$4.27m2.17%
$ 4.9m
Kevin Moran
Senior VP11.3yrsUS$1.44m0.093%
$ 207.2k
Timothy Williams
Senior VP5.6yrsUS$1.50m0.040%
$ 88.6k
Joakim Wijkstrom
Senior VP & Chief Marketing Officer4.6yrsUS$1.62m0.086%
$ 193.6k
Gunther Birznieks
Senior Vice President of Business Development7yrsUS$1.47m0.54%
$ 1.2m
Scott Howell
Chief People Officer4.6yrsno datano data
Elizabeth Van Every
Head of Corporate Affairsno datano datano data

6.3yrs

Average Tenure

53yo

Average Age

Experienced Management: VNDA's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mihael Polymeropoulos
Founder20.8yrsUS$4.27m2.17%
$ 4.9m
Richard Dugan
Lead Independent Director18.3yrsUS$317.08k0.12%
$ 266.0k
Tage Honore
Independent Directorless than a yearno datano data
Anne Ward
Independent Director4.4yrsUS$296.24k0.017%
$ 38.9k
Stephen Mitchell
Independent Director4.1yrsUS$279.99k0.021%
$ 46.8k
Phaedra Chrousos
Independent Director4.4yrsUS$294.06k0.022%
$ 50.3k

4.4yrs

Average Tenure

66.5yo

Average Age

Experienced Board: VNDA's board of directors are considered experienced (4.4 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.